January 27, 2020 -Clinical Synopsis
Patient Condition: 56-year-old female who has lymphedema, diabetes, hypertension, and is morbidly obese was admitted to Scarborough & Rouge Hospital presenting with a venous ulcer on her upper medial thigh that was triggered by a small trauma 3 years ago. Prior to incorporating the MolecuLight i:X into the patient’s treatment, many efforts with various dressings and
… Read MoreJanuary 27, 2020 -Fluorescence imaging has been used to visualize red-fluorescing, pathogenic bacteria in the wound bed and periwound area at the bedside using a non-contact, hand-held device. The visualization of bacterial load can be incorporated to optimize wound hygiene by guiding targeted cleansing and debridement. Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.